For all the benefits that fintech has brought to consumers, businesses and societies, it has also introduced new sources of vulnerability to financial systems, raising questions about the latter’s fragility.

Further to our January 2024 client alert, the anticipated amendments to the Enforcement Decree of the Financial Services and Capital Markets Act (“FSCMA Enforcement Decree”) have been adopted by the Korean government cabinet on 27 February 2024 and promulgated on 5 March 2024. The amendments to the FSCMA Enforcement Decree are therefore effective as of 5 March 2024.

As of 5 March 2024, domestic employees of multinational companies who have acquired shares under a stock-based compensation program may sell such shares without the involvement of a Korean broker and may deposit proceeds from the sale of shares into an account with an overseas financial institution. For any shares sold/funds deposited prior to this date, the previous restrictions applied and these transactions could therefore remain problematic if they did not comply with the restrictions.

From governments to private investors, big pharma to biotechs, organizations inside and outside the region are reimagining healthcare and life sciences to improve access, outcomes and affordability. This requires capital investment, collaboration and change at levels rarely seen before. In our digital campaign, we explore this dynamic through two main themes and identify six key market opportunities.

The FCA’s Sustainability Disclosure Requirements (SDR) regime is the UK’s flagship ESG regime, set to apply from May 2024 onwards. The SDR is primarily a product labelling regime which is accompanied by entity-level disclosure requirements, new anti-greenwashing guidance and ESG marketing requirements.
This implementation guide provides a practical overview of the regime and key points for firms to consider when launching an SDR labelled fund and completing entity-level disclosures.